Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China

Overview of attention for article published in Cost Effectiveness and Resource Allocation, August 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)

Mentioned by

blogs: 1 blog

twitter: 1 X user

Citations

dimensions_citation: 35 Dimensions

Readers on

mendeley: 46 Mendeley

Summary Blogs X Dimensions citations

So far, Altmetric has seen 1 blog post.

Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China

information for practice, 05 Aug 2018

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally. In China, sorafenib and oxaliplatin plus…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.